Validity of HB-EGF as Target for Human Neuroblastoma Therapy.

Abstract

BACKGROUND/AIM:

Neuroblastoma (NB) is the most common and lethal extracranial solid tumor in children. The present study aimed to verify that the heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a rational target in NB therapy.

MATERIAL AND METHODS:

We examined expression of EGFR ligands in four NB cell lines using 2-dimensional culture (DC) and 3DC conditions. To assess the anti-tumor effect of cross-reacting material 197 (CRM197), which is a specific inhibitor of HB-EGF, on NB cells, we also performed terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay to detect apoptotic cells.

RESULTS:

HB-EGF was predominantly expressed in two out of four NB cell lines under 2DC and 3DC conditions. CRM197 significantly induced apoptosis of NB cells with high HB-EGF expression.

CONCLUSION:

HB-EGF plays an important role in neuroblastoma tumorigenesis and CRM197 showed an effective antitumor effect in neuroblastoma cells.

• Authors: Sung Ouk Nam, Fusanori Yotsumoto, Kohei Miyata, Ryota Souzaki, Tomoaki Taguchi, Masahide Kuroki, Shingo Miyamoto
• Journal: Anticancer research (Anticancer Res) Vol. 35 Issue 8 Pg. 4433-40 (Aug 2015) ISSN: 1791-7530 [Electronic] Greece
• PMID: 26168483 (Publication Type: Journal Article)
• Copyright: Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Chemical References

• Bacterial Proteins
• Heparin-binding EGF-like Growth Factor
• CRM197 (non-toxic variant of diphtheria toxin)
• EGFR protein, human
• ErbB Receptors

Topics

• Apoptosis (drug effects)
• Bacterial Proteins (pharmacology)
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• ErbB Receptors (biosynthesis)
• Heparin-binding EGF-like Growth Factor (metabolism)
• Humans
• In Situ Nick-End Labeling
• Molecular Targeted Therapy
• Neuroblastoma (drug therapy)